Seeking Alpha

Valeant Pharmaceuticals Intl (VRX)

()
52wk high:
52wk low:
EPS:
PE:
Dividend:
Yield:
Market Cap:
Exchange:
Analysis - Latest Articles
Latest Transcript
Instablogs
  • Seth Klarman & Marty Whitman Are Sellers But Meryl Witmer Buys in Q3 2009
    Tue November 17, 2009 • Davy Bui • Comment!
  • Breakout Stocks on BIG Volume November 16, 2009 & RINO Detailed Option Trade
    Tue November 17, 2009 • Marco Hickey • Comment!
  • It Turns Out that Wrinkles Are Worth Quite a Lot
    Mon November 2, 2009 • Carol Flake Chapman • Comment!
Write a post on VRX | More Instablogs on VRX »
Sentiment
What advice would you give to
VRX?
124 characters left
Market Currents
  • Sunday 00:00 am Barron's Bill Alpert thinks investors are overestimating the potential of Valeant Pharmaceuticals' (VRX) prospective epilepsy drug (retigabine) to offset waning royalties from its top-selling antiviral drug ribavirin. Two key issues are widespread complaints of side effects by test subjects, and a fierce push by prescription-drug plans to move patients to generics. Comment!
What's your view of VRX?
Make sure you include VRX
140 characters left